ATEC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

209.19M

+18.33%

-0.136

-40.87%

204.22M

+20.71%

-0.178

-49.14%

215.00M

+15.88%

-0.104

-61.48%

Estimates Revision

The market is revising Upward the revenue expectations for Alphatec Holdings, Inc. (ATEC) for FY2025, with the revenue forecasts being adjusted by 2.51% over the past three months. During the same period, the stock price has changed by 64.61%.

Revenue Estimates for FY2025

Revise Upward

+2.51%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.97%

In Past 3 Month

Stock Price

Go Up

+64.61%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast ATEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATEC is 23.00 USD with a low forecast of 16.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

16.00

Averages

23.00

High

27.00

Current: 0.000

Low

16.00

Averages

23.00

High

27.00

Barclays

Overweight

maintain

$23 -> $27

2026-01-07

New

Reason

Barclays

Price Target

$23 -> $27

2026-01-07

New

maintain

Overweight

Reason

Barclays raised the firm's price target on Alphatec to $27 from $23 and keeps an Overweight rating on the shares. The firm cites the recent increase in comparable stocks for the target multiple boost.

Freedom Capital

Keith Hinton

Buy

initiated

$25

2025-12-10

Reason

Freedom Capital

Keith Hinton

Price Target

$25

2025-12-10

initiated

Buy

Reason

Freedom Capital analyst Keith Hinton initiated coverage of Alphatec with a Buy rating and $25 price target. The firm thinks the pure-play spine medtech company can continue to grow well above the market as the company leverages its differentiated strategy, lateral portfolio and growing scale to take share, the analyst tells investors.

Morgan Stanley

Equal Weight

maintain

$21 -> $23

2025-12-02

Reason

Morgan Stanley

Price Target

$21 -> $23

2025-12-02

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Alphatec to $23 from $21 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.

Morgan Stanley

Equal Weight

maintain

$16 -> $21

2025-11-10

Reason

Morgan Stanley

Price Target

$16 -> $21

2025-11-10

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Alphatec to $21 from $16 and keeps an Equal Weight rating on the shares.

Barclays

NULL -> Overweight

maintain

$22 -> $23

2025-11-03

Reason

Barclays

Price Target

$22 -> $23

2025-11-03

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Alphatec to $23 from $22 and keeps an Overweight rating on the shares. The firm says the company's strong surgical growth drove upside to Q3 sales estimates.

Lake Street

Buy

maintain

$18 -> $25

2025-10-31

Reason

Lake Street

Price Target

$18 -> $25

2025-10-31

maintain

Buy

Reason

Lake Street raised the firm's price target on Alphatec to $25 from $18 and keeps a Buy rating on the shares following "another beat-and-raise quarter" in Q3. Alphatec will continue to gain as the only scaled player focused on spine, contends the analyst, who adds that "underlying metrics suggest the company's strengths may well be growing."

Valuation Metrics

The current forward P/E ratio for Alphatec Holdings Inc (ATEC.O) is -41.19, compared to its 5-year average forward P/E of -15.02. For a more detailed relative valuation and DCF analysis to assess Alphatec Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-15.02

Current PE

-41.19

Overvalued PE

-7.06

Undervalued PE

-22.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

66.95

Current EV/EBITDA

30.11

Overvalued EV/EBITDA

252.91

Undervalued EV/EBITDA

-119.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.25

Current PS

3.60

Overvalued PS

4.59

Undervalued PS

1.90

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 316.57% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ATEC News & Events

Events Timeline

No data

News

5.0

2025-12-27Fool

Alphatec COO Scott Lish Sells Nearly 20,000 Shares for Approximately $390,836

5.0

2025-12-27NASDAQ.COM

Alphatec COO Scott Lish Sells 19,900 Shares for $390,836

9.5

2025-12-23NASDAQ.COM

Novo Nordisk (NVO) Gains 9.48% After FDA Approves Wegovy Obesity Pill

People Also Watch

Frequently Asked Questions

What is Alphatec Holdings Inc (ATEC) stock price today?

The current price of ATEC is 22.65 USD — it has decreased -0.13 % in the last trading day.

What is Alphatec Holdings Inc (ATEC)'s business?

Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. The Company is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. The Company's Organic Innovation Machine is focused on developing new approaches that integrate with its expanding Alpha InformatiX (AIX) Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include AIX, positioners, access systems, implants and fixation systems, and biologics. Its AIX product platform comprises its EOS imaging system and VEA alignment mobile application, its SafeOp Neural InformatiX System and its navigation-enabled robotics platform (Valence). It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.

What is the price predicton of ATEC Stock?

What is Alphatec Holdings Inc (ATEC)'s revenue for the last quarter?

Alphatec Holdings Inc revenue for the last quarter amounts to 196.50M USD, increased 30.38 % YoY.

What is Alphatec Holdings Inc (ATEC)'s earnings per share (EPS) for the last quarter?

Alphatec Holdings Inc. EPS for the last quarter amounts to -0.19 USD, decreased -32.14 % YoY.

What changes have occurred in the market's expectations for Alphatec Holdings Inc (ATEC)'s fundamentals?

How many employees does Alphatec Holdings Inc (ATEC). have?

Alphatec Holdings Inc (ATEC) has 867 emplpoyees as of January 10 2026.

What is Alphatec Holdings Inc (ATEC) market cap?

Today ATEC has the market capitalization of 3.36B USD.